Previous 10 | Next 10 |
BioMarin to Participate in Three Upcoming Virtual Investor Conferences - Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 1:15pm ET - BofA Global Healthcare Conference 2021 on September 17 at 12:35pm ET/5:35pm BST - J.P. Morgan 12th Annual U.S. ...
Obtaining U.S. Food and Drug Administration approval for a drug, even after multiple trials in various phases, is not the easiest thing for a pharma company to do. BioMarin (NASDAQ: BMRN) knows this as well as any company that has been rejected for approval in the past. And so do it...
BMRN has an upcoming PDUFA, and probably another for Roctavian next year. They recently raised full year guidance on the back of better than expected revenue from the last quarter. The stock looks like an excellent opportunity for longer-term investors. For further details s...
Gainers: ANAB +8.0%. TLRY +6.0%. TVTX +4.1%. AMRS +3.8%. LPRO +3.2%. Losers: AEPPL -11.1%. PFMT -10.5%. BMRN -8.0%. CDK -7.3%. LI -4.7%. For further details see: ANAB, TLRY, PFMT and BMRN among after hours movers
Image source: The Motley Fool. BioMarin Pharmaceutical inc (NASDAQ: BMRN) Q2 2021 Earnings Call Jul 28, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transc...
BioMarin Pharmaceutical Inc. (BMRN) Q2 2021 Results Conference Call July 28, 2021 04:30 PM ET Company Participants Traci McCarty - VP, IR J.J. Bienaimé - Chairman and CEO Jeff Ajer - EVP and Chief Commercial Officer Hank Fuchs - President, Worldwide Research and Development Greg Guyer - ...
Michael Vi/iStock Editorial via Getty Images BioMarin Pharmaceutical (BMRN) shares rise more than 3% post market after the company posted second-quarter results that beat Wall Street estimates, and raised its FY revenue forecast. The company's quarterly revenue increased ~17% to $50...
BioMarin Pharmaceutical (BMRN): Q2 GAAP EPS of $0.07 beats by $0.18.Revenue of $501.69M (+16.8% Y/Y) beats by $53.17M.2021 Guidance: Revenue: $1.79B - 1.88B from $1.75B - 1.85B vs. consensus of $1.82B; Vimizim: $580M - 620M from $570M - 610M; Kuvan: $260M - 290M; Naglazyme: $375M - 405M from ...
BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates - Total Revenues Grew 17% in the Second Quarter 2021 Compared to Second Quarter 2020 - Raising Full-year 2021 Financial Guidance - Marketing Authorization Application (MAA) for Valoctocogene R...
BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demonstrating Continued, Durable Clinical B...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease PR Newswire Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, C...
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...